Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Global Consensus on the Management of Primary Localized Chordoma.

JAMA oncology·2026
Same author

Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach.

American journal of clinical oncology·2026
Same author

Acidic bile salts induce APE1-dependent PRDX2 activation to drive oxaliplatin resistance via ferroptosis inhibition.

Redox biology·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Multidisciplinary Management of Esophageal Cancer.

JCO oncology practice·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

相关实验视频

Updated: Jul 28, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K

用于软组织肉瘤的CivaSheet®:一个单一机构的经验.

Crystal Seldon1, Julie G Grossman2, Gautam Shrivastava1

  • 1Department of Radiation Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.

Brachytherapy
|June 4, 2023
PubMed
概括

一种可植入的-103装置CivaSheet显示了通过提供向辐射来治疗软组织肉瘤 (STS) 的潜力. 初步结果显示,局部复发率为40%,在某些情况下出现4级并发症.

关键词:
支臂疗法是一种手臂疗法.在CivaSheet中使用.软组织肉瘤是软组织肉瘤.

更多相关视频

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Isolation of Primary Human Colon Tumor Cells from Surgical Tissues and Culturing Them Directly on Soft Elastic Substrates for Traction Cytometry
09:28

Isolation of Primary Human Colon Tumor Cells from Surgical Tissues and Culturing Them Directly on Soft Elastic Substrates for Traction Cytometry

Published on: June 4, 2015

15.6K

相关实验视频

Last Updated: Jul 28, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Isolation of Primary Human Colon Tumor Cells from Surgical Tissues and Culturing Them Directly on Soft Elastic Substrates for Traction Cytometry
09:28

Isolation of Primary Human Colon Tumor Cells from Surgical Tissues and Culturing Them Directly on Soft Elastic Substrates for Traction Cytometry

Published on: June 4, 2015

15.6K

科学领域:

  • 在瘤学瘤学.
  • 辐射瘤学 辐射瘤学
  • 医疗器械 医疗器械

背景情况:

  • 软组织肉瘤 (STS) 提出了治疗挑战,特别是在已经达到最大辐射耐受度的患者中.
  • 术内辐射疗法 (IORT) 提供了一种在手术期间提供向辐射剂量的方法.
  • 103 (Pd-103) 是一种放射性同位素,因其剂量计特性而用于胸膜疗法.

研究的目的:

  • 评估使用CivaSheet的初始临床经验和结果,CivaSheet是一种使用ladium-103.3的植入式术内放射治疗设备.
  • 评估CivaSheet在手术切除软组织肉瘤患者的安全性和有效性.
  • 确定与CivaSheet安置相关的本地复发率和并发症概况.

主要方法:

  • 在2018年1月至2019年12月期间,对通过外科切除和CivaSheet安置治疗的STS患者进行了回顾性图表审查.
  • 含有-103的CivaSheet设备,在5毫米的深度下,平均提供了47 Gy的辅助辐射剂量.
  • 患者数据包括瘤位置,大小,手术重建方法,局部复发和并发症.

主要成果:

  • 在9名STS患者身上植入了10张CivaSheets,平均随访时间为27个月.
  • 瘤的位置各不相同,包括尾,胸部,沟和下肢,平均瘤大小为7.6厘米.
  • 观察到40%的局部复发率. 三名患者出现了4级并发症,需要移除设备,特别是在先前进行放射和片重建的情况下. 肢体瘤显示高4级不良事件的高率.

结论:

  • CivaSheet代表了一种用于STS患者手术期间辐射增强的新方法.
  • 虽然显示出潜力,但观察到的局部复发和并发症率需要进一步调查.
  • CivaSheet可能是传统支臂治疗方法的可行替代品,但仔细的患者选择和监测至关重要.